Latest Articles
-
CNA: Big investors pour funds into longevity research, accelerating growth in field
By CNA’s DAWN TAN, Jan 2023
In the second of a four-part series that explores the idea of living longer, CNA’s Dawn Tan looks at the appeal of the longevity industry for investors and private sector firms.
Big investors are zeroing in on age reversal research by biotechnology firms, with massive funding accelerating the pace of such studies. Hong Kong-based Insilico Medicine is among the biotech firms benefitting from the interest.
Multiple investors have poured in more than US$400 million to support the firm since 2014. Among its biggest backers is Pavilion Capital, a wholly owned subsidiary of Singapore's sovereign wealth fund Temasek Holdings.
Dr Alex Zhavoronkov, chief executive of Insilico Medicine, said Singapore is one of the major hubs for longevity research.
“Singapore is betting on future techn